IRIS Accounts Production v25.1.4.42 09053630 Board of Directors 1.6.24 31.5.25 31.5.25 false true false false true false Ordinary A 1.00000 4187 11009 4402 7272 10312 450 10097 4187 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh090536302024-05-31090536302025-05-31090536302024-06-012025-05-31090536302023-05-31090536302023-06-012024-05-31090536302024-05-3109053630ns15:EnglandWales2024-06-012025-05-3109053630ns14:PoundSterling2024-06-012025-05-3109053630ns10:Director12024-06-012025-05-3109053630ns10:PrivateLimitedCompanyLtd2024-06-012025-05-3109053630ns10:SmallEntities2024-06-012025-05-3109053630ns10:AuditExempt-NoAccountantsReport2024-06-012025-05-3109053630ns10:SmallCompaniesRegimeForDirectorsReport2024-06-012025-05-3109053630ns10:SmallCompaniesRegimeForAccounts2024-06-012025-05-3109053630ns10:FullAccounts2024-06-012025-05-3109053630ns10:OrdinaryShareClass12024-06-012025-05-3109053630ns10:Director2422024-05-3109053630ns10:Director2422023-05-3109053630ns10:Director2422024-06-012025-05-3109053630ns10:Director2422023-06-012024-05-3109053630ns10:Director2422025-05-3109053630ns10:Director2422024-05-3109053630ns5:CurrentFinancialInstruments2025-05-3109053630ns5:CurrentFinancialInstruments2024-05-3109053630ns5:ShareCapital2025-05-3109053630ns5:ShareCapital2024-05-3109053630ns5:RetainedEarningsAccumulatedLosses2025-05-3109053630ns5:RetainedEarningsAccumulatedLosses2024-05-3109053630ns10:RegisteredOffice2024-06-012025-05-3109053630ns5:FurnitureFittings2024-05-3109053630ns5:FurnitureFittings2025-05-3109053630ns5:FurnitureFittings2024-05-3109053630ns10:OrdinaryShareClass12025-05-3109053630ns10:Director22024-06-012025-05-31090536301ns10:Director12024-05-31090536301ns10:Director12023-05-31090536301ns10:Director12024-06-012025-05-31090536301ns10:Director12023-06-012024-05-31090536301ns10:Director12025-05-31090536301ns10:Director12024-05-31
REGISTERED NUMBER: 09053630 (England and Wales)















Unaudited Financial Statements for the Year Ended 31st May 2025

for

Sycamore Life Sciences Limited

Sycamore Life Sciences Limited (Registered number: 09053630)






Contents of the Financial Statements
for the Year Ended 31st May 2025




Page

Balance Sheet 1

Notes to the Financial Statements 2


Sycamore Life Sciences Limited (Registered number: 09053630)

Balance Sheet
31st May 2025

31.5.25 31.5.24
Notes £    £   
CURRENT ASSETS
Cash at bank 7,213 2,448

CREDITORS
Amounts falling due within one year 5 10,740 4,782
NET CURRENT LIABILITIES (3,527 ) (2,334 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(3,527

)

(2,334

)

CAPITAL AND RESERVES
Called up share capital 6 1,000 1,000
Retained earnings (4,527 ) (3,334 )
SHAREHOLDERS' FUNDS (3,527 ) (2,334 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st May 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st May 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 12th August 2025 and were signed on its behalf by:





Dr A B Abhyankar - Director


Sycamore Life Sciences Limited (Registered number: 09053630)

Notes to the Financial Statements
for the Year Ended 31st May 2025

1. COMPANY INFORMATION

Sycamore Life Sciences Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address are as below:

Registered number: 09053630

Registered office: The Lexicon
Mount Street
Manchester
M2 5NT

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Tangible fixed assets
Tangible Fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment loss.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following basis:

Fixtures and Fittings - 25% on cost

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to the profit or loss.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Sycamore Life Sciences Limited (Registered number: 09053630)

Notes to the Financial Statements - continued
for the Year Ended 31st May 2025

2. ACCOUNTING POLICIES - continued

Going concern
Due to the the impact of the covid19 pandemic the company reports negative reserves at the balance sheet date. However, the directors are of the opinion that this is likely to change in the next financial year and they will continue to support the company as they have done throughout the current year. At the time of approving the financial statements, the directors have a reasonable expectation that the company will have adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2024 - 2 ) .

4. TANGIBLE FIXED ASSETS
Fixtures
and
fittings
£   
COST
At 1st June 2024
and 31st May 2025 2,453
DEPRECIATION
At 1st June 2024
and 31st May 2025 2,453
NET BOOK VALUE
At 31st May 2025 -
At 31st May 2024 -

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.5.25 31.5.24
£    £   
Directors' current accounts 10,097 4,187
Accrued expenses 643 595
10,740 4,782

6. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 31.5.25 31.5.24
value: £    £   
1,000 Ordinary A £1 1,000 1,000

Sycamore Life Sciences Limited (Registered number: 09053630)

Notes to the Financial Statements - continued
for the Year Ended 31st May 2025

7. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to directors subsisted during the years ended 31st May 2025 and 31st May 2024:

31.5.25 31.5.24
£    £   
Dr A B Abhyankar and Dr B A Abhyankar
Balance outstanding at start of year (4,187 ) (11,009 )
Amounts advanced 4,402 7,272
Amounts repaid (10,312 ) (450 )
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year (10,097 ) (4,187 )

The loan is repayable on demand and no interest was charged during the year.

8. ULTIMATE CONTROLLING PARTY

The company is under the joint control of the directors by virtue of their joint holding of 100% of the voting share capital.